|Day Low/High||50.56 / 52.76|
|52 Wk Low/High||50.56 / 70.05|
Rising oil prices, surging bond yields and mixed earnings forecasts have stalled overnight gains for global stocks and pulled U.S. equity futures into the red ahead of another hectic slate of corporate reports.
Let's look at the charts this afternoon.
Jim Cramer highlights Wendy's, Spirit AeroSystems, Dunkin Brands, Bristol-Meyers Squibb, Take-Two Interactive and more.
Jim Cramer says it was utter insanity. In earnings, these executives said exactly the wrong things.
Stocks rise Monday as concerns over prolonged military action in Syria fade and the focus for investors shifts to a heavy upcoming slate of U.S. corporate earnings.
Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.
Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!
The drugmakers on April 16 released data from their respective studies at the Association for Cancer Research's annual meeting in Chicago.
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
Let's puzzle over Syria and the possibility of another 'Saturday Night Massacre.'
If President Trump is too busy to post anti-Amazon tweets, that's good news for the online retailer.
Why you can't blame the president for Wednesday's weakness.
But If you want to know what I think could work the loudest here? How about Amazon?
The fatality that came at the hands of a self-driving Uber vehicle was tragic. But keep in mind, self-driving cars will be safer than human drivers in the not-too-distant future.
Bristol-Myers Squibb Company (NYSE: BMY) will hold an investor event on Monday, April 16, 2018 at 6:00 p.
Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf...
For Women's History Month, Alpha Rising sat down with Nancy Lieberman, Of Counsel at Skadden, Arps. She was and still is the youngest person to ever make partner at her firm. She has worked on some of the biggest M&A deals in history -- and we should mention -- she's in a wheelchair and barely as use of her hands. Feel like a slacker yet? Good. Watch.
Pomerantz LLP announces that a class action lawsuit has been filed against Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY) and certain of its officers.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of an every four-week (Q4W) Opdivo...
Let's check out the charts and indicators for some guidance.
Value stocks haven't done well in the era of easy money, with cash piling into growth names. But, that could be about to change.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bristol-Myers Squibb Company (NYSE: BMY) from January 27, 2015 through October 9, 2016, inclusive (the "Class Period") of the...
Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.